ViroPharma Gets Good News And Bad News On Cinryze From FDA

sBLA for acute angioedema treatment gets a “complete response,” putting Cinryze into the losers’ bracket contesting for the first U.S. acute HAE approval. Drug’s prophylactic labeling, meanwhile, is amended to allow self-administration.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet